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Arresting kinase suppressor of Ras in an 
inactive state
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Abstract 
Ras protein signaling pathways are important in controlling the plight of different types of cancer. Here we discussed 
the paper entitled “Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling” 
published in Nature journal on inactivating the kinase suppressor of Ras (KSR) protein using a small molecule as an 
inhibitor by Dhawan et al. A biphenyl ether analogue of a quinazoline binds in one of the binding pockets of KSR and 
results in stabilization of its inactive state. In this inactive state, KSR is unable to take part in the cascade of protein 
association to perform the signalling process.
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Ras proteins are a small guanine nucleotide-hydrolyzing 
proteins that play important roles in cell growth and 
spread in the mitogen-activated protein kinase (MAPK) 
signaling pathway [1]. Ras is the most mutated gene that 
is involved in almost one-third of all cancers [2, 3]. The 
kinase suppressor of Ras (KSR) works as a scaffold for 
the Ras/MAPK pathway [4, 5]. A number of studies have 
been conducted to target RAS protein using small mole-
cules as inhibitors [3]. These studies includes the nucleo-
tide exchange blockage [6, 7], Ras association with son of 
sevenless homologue (SOS) [8–10], and Ras–Raf interac-
tion [11, 12]. In the past, some approaches were used to 
target Ras via the KSR due to its pseudokinase standing 
and non-catalytic function, but now it is a more favora-
ble targeted pathway for designing drugs [13, 14]. The 
RAS–RAF–KSR–MEK1 pathway proteins work in a cas-
cade. Each protein in this pathway offer an opportunity 
to target the Ras mutation-related cancers by developing 
more powerful therapeutics [15–17]. In one of the study, 
a small molecule called rigosertib, which is a styryl-ben-
zyl sulfone binds with a Ras-binding domain (RBD) and 
causes the dissociation of RAS and RAF, resulting in inhi-
bition of the RAS–RAF–MEK pathway [13].
Recently, Dhawan et al. [14] published a paper entitled 
“Small molecule stabilization of the KSR inactive state 
antagonizes oncogenic Ras signalling” in Nature journal. 
They targeted the RAS signaling pathway by interfering 
in KSR, using small molecules as inhibitors that arrest the 
KSR–MEK1 in an inactive conformational state. Dhawan 
et al. [14] started their work on the hypothesis that if the 
KSR–MEK1 interface is disrupted through small mol-
ecules that can bind within the adenosine triphosphate 
(ATP)-binding pocket, these small molecules may disrupt 
the signaling pathway. They expected that if they used an 
inhibitor that take the structure of KSR into a similar state 
in complex with MEK1 and ATP as in the recent crystal 
structure form, it will not be possible for KSR to regulate 
RAF and MEK proteins. They screened 176 kinase inhibi-
tor compounds that are structurally different and target 
the ATP-binding pocket of the KSR2–MEK1 complex. 
Among those screened compounds, a quinazoline-biphe-
nyl ether named APS-1-68-2 (Fig.  1) is a strong com-
petitor for the ATP-binding pocket of the KSR2–MEK1 
complex. Through the structure–activity relationship 
analysis, they found a more potent inhibitor of APS-1-68-
2, where a methyl group is attached with the first phenyl 
ring of biphenyl ether, and named it APS-2-79 (Fig.  2). 
The 50% inhibiting concentration (IC50) of KSR2 was 
120 ± 23 nmol/L. In an in vitro assay, the phosphorylation 
of MEK Ser218 and Ser222 by RAF is enhanced in the 
presence of KSR but greatly reduced when APS-2-79 is 
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added. Thus, APS-2-79 works as an antagonist and stops 
the activity of RAF by binding with KSR. 
Dhawan et  al. [14] resolved the crystal structure of 
KSR2–MEK1 with APS-2-79. The APS-2-79 luckly hold 
the same binding pocket like that of ATP within the KSR2 
protein in the KSR2–MEK1 complex. Inside the binding 
pocket, the terminal phenyl ring of biphenyl ether group 
of APS-2-79 makes π-stacking interactions with Phe725, 
Tyr714, and Phe804 of KSR2. Removal of this phenyl side 
group from the main compounds leads to inactivity and 
loss of competitive ability for the binding pocket and that 
is why this side group makes it highly selective for KSR2. 
A hydrogen bond also exists between N-1 of quinazoline 
of APS-2-79 and Cys742 of KSR2. Dhawan et al. [14] con-
cluded that by binding APS-2-79 in the KSR2 pocket and 
making complex with MEK1, this complexation causes 
deep burying of the Ser218 and Ser222 of MEK1 onco-
protein. Thus, these two serine residues of MEK1 are not 
available for phorophorylation by RAF, resulting in the 
inhibition of signaling. The APS-2-79 arrest the KSR2-
MEK1 into an inactive state, resulting in an off state of 
the complex, and heterodimerization of KSR–RAF is not 
possible. This inhibition of RAF–KSR dimerization was 
further confirmed by mutagenic tests.
The use of small-molecule inhibitors that interact with 
different kinases and pseduokinases, especially the RAS 
pathway proteins, is a promising strategy for cancer cure. 
Similarly, due to continuous drug resistance, structure-
based drug design and covalent binding inhibitors for RAS 
signaling pathways should also be considered [18, 19].
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Fig. 1 Chemical structure of APS-1-68-2, a quinazoline heterocycle 
with attached biphenyl ether group [14]. (This figure is republished 
with permission from both the Nature Publishing Group and Dr. Arvin 
Dar)
Fig. 2 Chemical structure of APS-2-79, a quinazoline heterocycle and 
side group of biphenyl ether with attached methyl group [14]. (This 
figure is republished with permission from both the Nature Publish-
ing Group and Dr. Arvin Dar)
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